Three months into the novel coronavirus pandemic, its still unclear which drugs could combat the viral disease and which wont, despite public figures like President Donald Trump extolling the unproven promise of some medications. With public health on the line, the scientific community is searching for answers faster than ever.
When the novel coronavirus tore through China in January and February, researchers and doctors quickly launched dozens of clinical trials to test existing medications against COVID-19, the disease caused by the novel coronavirus. But the research done so far in China hasnt generated enough data for conclusive answers.
We commend the researchers around the world who have come together to systemically evaluate experimental therapeutics, said Tedros Adhanom, director-general of the World Health Organization (WHO), in a press briefing. Multiple small trials with different methodologies may not give us the clear, strong evidence we need about which treatments help to save lives.
In their fight for clear, strong evidence, the WHO is launching a multicountry clinical trial to test four drug regimens as COIVD-19 therapies: an experimental antiviral drug called remdesivir, the antimalarial drug chloroquine (or the related hydroxychloroquine), a combination of two HIV drugs, and those same two HIV drugs along with the anti-inflammatory interferon beta.
The trial will be flexible and could add or drop additional treatment approaches or locations over time. In that way, it appears to be similar to the adaptive trial that the National Institute of Allergy and Infectious Diseases started in the US in February, which initially set out to test remdesivir but could expand to other drugs. The US is not currently involved in the WHO trial.
Hundreds of other clinical trials are underway, and other groups also continue to test the medications that the WHO selected heres a breakdown of some of the drugs that researchers are zeroing in on.
Studies found that hydroxychloroquine and the related chloroquine can stop the novel coronavirus from infecting in cells in the lab, and anecdotal evidence suggests that it may help patients with COVID-19. Because the drug has been around for decades as an antimalarial treatment, scientists have experience with it.
Its a known medicine, says Caleb Skipper, an infectious disease postdoctoral fellow at the University of Minnesota whos working on a smaller trial of the drug. Little blips of lab data over the last several years show this drug has activity against viruses.
Skippers trial is looking to see if hydroxychloroquine can prevent people who are exposed to the virus from developing severe disease. Theyre hoping to recruit health care workers, who are at a high risk of exposure to the virus, to participate in the trial.
The goal, Skipper says, is to get the drug in peoples systems early. Particularly with viruses, the earlier you inhibit their ability to replicate the better off youre going to be. If a drug is going to work, it is more likely to work early on in disease, he says. If you catch someone really early and provide treatment early virus will have replicated a lot less.
The existing evidence on hydroxychloroquine points in the right direction, Skipper says, but all of the research on the drug is still in very early stages. Its a long ways from being proven effective, he says.
Despite the limited evidence available, public figures, including Elon Musk and Trump, are pushing the message that hydroxychloroquine and chloroquine are the solutions to the outbreaks. I feel good about it. Thats all it is, just a feeling, you know, smart guy. I feel good about it, Trump said in a press conference on Friday.
As a result of the hype, demand for the drug has spiked, and manufacturers are increasing production. In Nigeria, two people overdosed on the medication after Trump said it could cure COVID-19. People who take it for other conditions, like lupus, are struggling to access their usual supply.
To be very clear, there is still no conclusive evidence that chloroquine will treat COVID-19. And treatments that appear promising based on anecdotal reports or feelings often dont end up working, which scientists know well: the majority of clinical trials fail, and theyre seeing that reinforced in coronavirus treatment efforts.
In February, doctors in Thailand said they saw their COVID-19 patients improve on the combination of two HIV drugs, lopinavir-ritonavir. The WHO is testing the drug combination in their trial, along with anti-inflammatory interferon beta, which the body produces naturally to ward off viruses. The drug combination was used in patients during the SARS and MERS outbreaks, and it appeared to help.
But a clinical trial of those two drugs in China just found that patients with COVID-19 who were given the drugs did not improve more quickly than patients who didnt receive it.
The study, which was published this week, focused on a group of 199 severely ill patients, which may be why the drug wasnt effective the patients were already too sick. But Timothy Sheahan, a coronavirus expert and assistant professor at the University of North Carolina Gillings School of Global Public Health, says he wasnt surprised the drug didnt work. Weve done work on that particular drug cocktail, he says. The fact it failed is totally in step with everything weve done in the past.
The antiviral drug remdesivir was first developed to treat Ebola, but research later showed that it could also block MERS and SARS in cells. Lab tests have shown that it can inhibit the novel coronavirus in cells as well.
Theres also anecdotal evidence that remdesivir helps treat COVID-19 patients, but thats also no guarantee that a clinical trial will show that it works better than a placebo. Thats why the data collected on the drug through the WHO trial, the US adaptive trial, and the other studies is so important: before giving it to sick people en mass, doctors have to be sure that it actually works.
Though not a part of the WHO trial, Chinese officials also reported that the Japanese anti-flu drug favipiravir, which it tested in clinical trials, was effective in treating COVID-19 patients. Japan is studying the drug more closely, though data from those trials on the drug has not yet been published.
Based on the drugs antiviral activity in cells, Sheahan says hed be surprised if this drug ultimately ended up being effective. It doesnt work against MERS in cells, he says, and MERS is similar to the novel coronavirus.
In addition, some pharmaceutical companies are looking to repurpose anti-inflammatory drugs to try to calm lung inflammation in people with severe cases of COIVD-19; others are identifying the protective antibodies that people develop after theyre infected with the virus in an effort to manufacture a treatment.
Clinical trials take time to collect data properly, so there likely wont be concrete evidence until next month or later. Patients are already receiving these drugs through compassionate use programs, which allows doctors to order experimental medications in certain cases, and under off-label use, where doctors prescribe drugs outside of what theyre approved for.
But ensuring the clinical trial process takes place alongside that, before jumping to conclusions about the best course of action, ensures patients can be treated based on evidence.
The sheer number of trials going on around the world for each particular treatment approach will give researchers more data to work with and data from different groups of people. The more populations you can show a particular intervention works or does not work for, the more valuable that is, Skipper says. The bigger the amount of data available, the better.
The Verge
Vanguard
Related
Read more from the original source:
Scientists are racing to find the best drugs to treat COVID-19 - Vanguard
- 7 Reasons to Retire and Relocate When Savings Fall Short ... - ThinkAdvisor - October 9th, 2023 [October 9th, 2023]
- Strive Asset Management vs. Engine No. 1: How Did the Activists ... - Morningstar - September 21st, 2023 [September 21st, 2023]
- New Taskforce to build UK nuclear skills - GOV.UK - July 31st, 2023 [July 31st, 2023]
- National Bank of Canada FI Has $16.22 Million Position in ... - Defense World - June 26th, 2023 [June 26th, 2023]
- RIT part of National Science Foundation grant to help spur next ... - Rochester Institute of Technology - May 22nd, 2023 [May 22nd, 2023]
- 2023 NAIA Outdoor Track & Field Regional Awards - U.S. Track & Field and Cross Country Coaches Association - May 22nd, 2023 [May 22nd, 2023]
- P&I wins ASBPE national gold award for managers microsite - Pensions & Investments - May 22nd, 2023 [May 22nd, 2023]
- The National - January 30th, 2023 [January 30th, 2023]
- Dimon Highlights Need For More Oil And Gas Investment As Vanguard Bails On ESG Group - Forbes - December 16th, 2022 [December 16th, 2022]
- About Us | National Vanguard - November 19th, 2022 [November 19th, 2022]
- Vanguard News Network - October 11th, 2022 [October 11th, 2022]
- Retirement Clearinghouse Announces Auto-Portability Network with Fidelity, Vanguard and Alight | PLANSPONSOR - PLANSPONSOR - October 11th, 2022 [October 11th, 2022]
- Abenaa Jones named Ann Atherton Hertzler Early Career Professor - Pennsylvania State University - August 6th, 2022 [August 6th, 2022]
- City of Detroit, Charles H. Wright Museum of African American History, join the Black Theatre Network (BTN) to host Broadway Comes Home to Detroit, a... - July 25th, 2022 [July 25th, 2022]
- California Senate Votes to Keep Legalized Slavery in its Prisons - The Peoples Vanguard of Davis - June 29th, 2022 [June 29th, 2022]
- Schneider National (NYSE:SNDR) Now Covered by Analysts at Credit Suisse Group - Defense World - June 29th, 2022 [June 29th, 2022]
- Introducing the Truckstop.com Partner Marketplace: A Comprehensive Transportation and Logistics Ecosystem Empowering the Freight Community - Yahoo... - June 29th, 2022 [June 29th, 2022]
- A Pilgrimage to the Birthplace of the Modern Womens Rights Movement - AFAR Media - June 29th, 2022 [June 29th, 2022]
- White Child Adopted by Black Reality TV Star Beaten to Death - June 24th, 2022 [June 24th, 2022]
- National Car Rental - Wikipedia - June 24th, 2022 [June 24th, 2022]
- Down 15% in 2022, is it time to jump on Vanguard Australian Shares Index ETF? - The Motley Fool Australia - June 24th, 2022 [June 24th, 2022]
- LIVE BLOG: 2022 Corps at the Crest - San Diego - FloMarching - June 24th, 2022 [June 24th, 2022]
- Greater Sacramento Attends Bio International Convention in San Diego - The Peoples Vanguard of Davis - June 22nd, 2022 [June 22nd, 2022]
- Vanguard International Semiconductor : VIS and National Yang Ming Chiao Tung University Cofound Intelligent Manufacturing and Management Laboratory -... - June 22nd, 2022 [June 22nd, 2022]
- The Shadow Of June 12 - The Left and Nigeria's Democratic Revolution, By Baba Aye - SaharaReporters.com - June 22nd, 2022 [June 22nd, 2022]
- Yolo County Honors Juneteenth with Celebration - The Peoples Vanguard of Davis - June 22nd, 2022 [June 22nd, 2022]
- Commentary: Why San Francisco May Not Be the Best Test Case for Progressivism - The Peoples Vanguard of Davis - June 22nd, 2022 [June 22nd, 2022]
- As tennis fans gather Wimbledon worries expansion won't get over the line - The National - June 22nd, 2022 [June 22nd, 2022]
- Vanguard Charitable survey: More than 1 in 3 American donors gave half or more of their charitable contributions to disaster relief efforts in the... - May 20th, 2022 [May 20th, 2022]
- National Grid warns on cost-of-living challenges after strong profit (NYSE:NGG) - Seeking Alpha - May 20th, 2022 [May 20th, 2022]
- Is it a good time to buy the Vanguard Australian Shares Index ETF? - The Motley Fool Australia - May 20th, 2022 [May 20th, 2022]
- Student Opinion: The Biden Administration and Cable Companies Working Together to Bring Internet to Millions of Households - The Peoples Vanguard of... - May 20th, 2022 [May 20th, 2022]
- THE POWER OF LEADERSHIP - THISDAY Newspapers - May 20th, 2022 [May 20th, 2022]
- Vanguard may be shorting much vaunted 'owners' of its low-cost index funds as it upshifts to more Wall Street-style exec-comp tactics to thwart... - May 17th, 2022 [May 17th, 2022]
- Opinion | BlackRock, Vanguard and State Street Control a Piece of Nearly Everything - The New York Times - May 17th, 2022 [May 17th, 2022]
- Somalis receive explosive threat reduction training | Shephard - Shephard News - May 17th, 2022 [May 17th, 2022]
- JV Article: Platinum Group Metals is at the vanguard of next generation lithium-ion batteries - The Northern Miner - May 17th, 2022 [May 17th, 2022]
- Neo-Nazi Alex Davies guilty of belonging to banned terror group National Action - Tell MAMA - May 17th, 2022 [May 17th, 2022]
- Firearm-Related Homicides Reach an Unprecedented Level in the 21st Century - The Peoples Vanguard of Davis - May 17th, 2022 [May 17th, 2022]
- Satellites, the Space Race, and Supercomputing: How NASA Goddard's Beowulf Cluster Computer Became an Award-Winning Space Technology - NASA (.gov) - May 17th, 2022 [May 17th, 2022]
- Vanguard may be shorting much vaunted 'owners' of its low-cost index funds as it shifts to Wall Street-style exec-comp tactics to thwart competitors... - May 15th, 2022 [May 15th, 2022]
- Senate Democrats Fail to Codify Abortion Rights; Don't Have Votes to Overcome Filibuster Dem Manchin Votes with GOP - The Peoples Vanguard of Davis - May 15th, 2022 [May 15th, 2022]
- The School Buzz: Vanguard rocketry team competing for national title - KRDO - May 9th, 2022 [May 9th, 2022]
- The Anglo-Indian-Nigerian designer at the vanguard of British fashion - The National - May 9th, 2022 [May 9th, 2022]
- Candidate for Yolo County District Attorney Cynthia Rodriguez Announced Her Growing List of Endorsements in a Press Release on Thursday - The Peoples... - May 9th, 2022 [May 9th, 2022]
- Commentary: Trends Are Pushing Tech, Housing Toward Sacramento Region - The Peoples Vanguard of Davis - May 9th, 2022 [May 9th, 2022]
- UK Government announces 2 billion investment into nuclear submarines - The National - May 9th, 2022 [May 9th, 2022]
- Workers grapple with new stresses as they return to office - Tampa Bay Times - May 9th, 2022 [May 9th, 2022]
- Who is Ib Kamara, the new Off-White art director to fill Virgil Abloh's shoes? - The National - May 9th, 2022 [May 9th, 2022]
- Vanguard Lions Defeat Statesmen To End The Year - Victory Sports Network - April 15th, 2022 [April 15th, 2022]
- Other days - Arkansas Online - April 15th, 2022 [April 15th, 2022]
- Democrats are in danger of losing three congressional strongholds in South Texas - Standard-Times - April 15th, 2022 [April 15th, 2022]
- Remembering the WNBA's Portland Fire - Vanguard - Psuvanguard.com - April 13th, 2022 [April 13th, 2022]
- Honoring the life of Amara Marluke - Vanguard - Psuvanguard.com - April 13th, 2022 [April 13th, 2022]
- The grim outlook of owning and renting - Vanguard - Psuvanguard.com - April 13th, 2022 [April 13th, 2022]
- 2022 NAIA Women's Outdoor Track & Field Rating Index Week 3 - U.S. Track & Field and Cross Country Coaches Association - April 13th, 2022 [April 13th, 2022]
- ECOWAS and Nigeria Agree on a Roadmap to Institutionalise a Government and Society Wide Approach - African Business - March 17th, 2022 [March 17th, 2022]
- LA Treasurer joins other states in divesting Russian investments - KATC News - March 8th, 2022 [March 8th, 2022]
- How the US and Europe helped Ukraine prep for insurgency - ArmyTimes.com - March 8th, 2022 [March 8th, 2022]
- A Trailblazing Engineer Says Invention Is in Everything I Do - Tufts Now - March 8th, 2022 [March 8th, 2022]
- Russias Invasion of Ukraine and Implications for the Korean Peninsula - Council on Foreign Relations - March 8th, 2022 [March 8th, 2022]
- Vanguard University saying goodbye to the Pit - Los Angeles Times - January 14th, 2022 [January 14th, 2022]
- Energy Ended Up as a Good Bet Last Year. But Now What? - The New York Times - January 14th, 2022 [January 14th, 2022]
- Kensington Vanguard National Land Services - December 19th, 2021 [December 19th, 2021]
- Barry Harris, Pianist and Devoted Scholar of Bebop, Dies at 91 - The New York Times - December 10th, 2021 [December 10th, 2021]
- From Our Archives: a Profile of Bob Dole, Once the Senate's "Funniest Member" - Washingtonian - December 7th, 2021 [December 7th, 2021]
- National Auto Care on acquisition spree amid F&I consolidation - Automotive News - December 5th, 2021 [December 5th, 2021]
- A decade of marketisation has left lecturers with no choice but to strike - The Guardian - December 5th, 2021 [December 5th, 2021]
- A New Vanguard Is Reshaping the Art World - HarpersBAZAAR.com - December 5th, 2021 [December 5th, 2021]
- Opinion | The Trump Conspiracy Is Hiding in Plain Sight - The New York Times - December 5th, 2021 [December 5th, 2021]
- The forgotten importance of the War of Jenkins' Ear - The Economist - December 5th, 2021 [December 5th, 2021]
- What Conservative Critics of Higher Education Share - The Atlantic - December 5th, 2021 [December 5th, 2021]
- The Unite the Right trial is exposing the chasm between who plans White nationalism's battles and who does the fighting - ABC17News.com - November 19th, 2021 [November 19th, 2021]
- Tordue Salem: Journalists ask National Assembly to order independent inquiry into death of missing reporter - Premium Times - November 19th, 2021 [November 19th, 2021]
- Abu Dhabi to Welcome Two New Museums in Addition to Guggenheim and Zayed - Artforum - November 19th, 2021 [November 19th, 2021]
- Gauteng government at the vanguard of SAs green economy plans - Business Day - November 17th, 2021 [November 17th, 2021]
- 25 years of school and family connections | Hub - The Hub at Johns Hopkins - November 17th, 2021 [November 17th, 2021]
- Opinion: Organized crime is a top driver of global deforestation and climate change - Houston Chronicle - November 17th, 2021 [November 17th, 2021]
- Letters to the editor: Lend a hand to these family caregivers - Austin American-Statesman - November 15th, 2021 [November 15th, 2021]
- University of Chicago to award four honorary degrees at 2022 Convocation - UChicago News - November 9th, 2021 [November 9th, 2021]